or Try an Advanced Search...

    Technical Analysis for ATXS - Astria Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 11.87 4.95% 0.56
    ATXS closed up 4.95 percent on Friday, October 4, 2024, on 67 percent of normal volume. It was able to find support at its 50 day moving average.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ATXS trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Fell Below 20 DMA Bearish 4.95%
    50 DMA Support Bullish 4.95%
    Calm After Storm Range Contraction 4.95%
    NR7 Range Contraction 4.95%
    Inside Day Range Contraction 4.95%
    Older End-of-Day Signals for ATXS ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 19 hours ago
    Rose Above Previous Day's High about 20 hours ago
    Outside Day about 20 hours ago
    Up 3% about 20 hours ago
    20 DMA Support about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ATXS Chart by TradingView
    Basic chart:

    Profile

    Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Immunology Monoclonal Antibody Antibody Angioedema Hereditary Angioedema Kallikrein Complement Deficiency

    Is ATXS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 30 Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
    Sep 27 Astria Therapeutics to Present at Upcoming Global Angioedema Forum
    Sep 19 Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
    Aug 30 Astria Therapeutics to Present at Upcoming Bradykinin Symposium
    Aug 29 Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
    Aug 12 Astria Therapeutics GAAP EPS of -$0.43 misses by $0.03
    Aug 12 Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
    Aug 12 Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
    Aug 7 Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
    Jun 24 Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field
    See more ATXS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.9
    52 Week Low 4.26
    Average Volume 361,808
    200-Day Moving Average 10.94
    50-Day Moving Average 11.30
    20-Day Moving Average 11.45
    10-Day Moving Average 11.48
    Average True Range 0.74
    RSI (14) 54.13
    ADX 16.56
    +DI 17.22
    -DI 19.63
    Chandelier Exit (Long, 3 ATRs) 10.70
    Chandelier Exit (Short, 3 ATRs) 12.49
    Upper Bollinger Bands 12.63
    Lower Bollinger Band 10.28
    Percent B (%b) 0.68
    BandWidth 20.56
    MACD Line 0.04
    MACD Signal Line 0.06
    MACD Histogram -0.0152
    Fundamentals Value
    Market Cap 648.89 Million
    Num Shares 54.7 Million
    EPS -2.12
    Price-to-Earnings (P/E) Ratio -5.60
    Price-to-Sales 0.00
    Price-to-Book 9.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.94
    Resistance 3 (R3) 12.83 12.37 12.76
    Resistance 2 (R2) 12.37 12.10 12.42 12.70
    Resistance 1 (R1) 12.12 11.93 12.25 12.23 12.64
    Pivot Point 11.66 11.66 11.72 11.71 11.66
    Support 1 (S1) 11.41 11.39 11.54 11.52 11.10
    Support 2 (S2) 10.95 11.22 11.00 11.04
    Support 3 (S3) 10.70 10.95 10.98
    Support 4 (S4) 10.81